Consequently, our study sought to evaluate the role of lncRNA IGFL2-AS1 as a therapeutic target in CRC and confer a novel theoretical basis for the suppression of CRC cell malignant proliferation. The gene discussed is IGFL2; the disease is colorectal carcinoma.